Motley Fool Asset Management LLC Has $8.01 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Motley Fool Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 0.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 141,649 shares of the biopharmaceutical company’s stock after purchasing an additional 360 shares during the period. Motley Fool Asset Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $8,005,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $33,000. UMB Bank n.a. lifted its position in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares in the last quarter. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $43,000. Values First Advisors Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $56,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $107,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.46.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $46.67 on Wednesday. The company has a fifty day moving average price of $51.63 and a 200-day moving average price of $48.79. The firm has a market capitalization of $4.31 billion, a P/E ratio of -7.21 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period in the previous year, the business earned ($2.23) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.